News | May 21, 2026
Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Minister J.P. Nadda holds bilateral meeting with Helen Clark, Board Chair of the Partnership for Maternal, Newborn and Child Health in Geneva
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Subscribe To Our Newsletter & Stay Updated
